Published: 11 April 2017
Author(s): Anna Gallotta, Alessandra Marengoni, Luca Pasina, Laura Cortesi, Alessandro Nobili
Issue: April 2017
Section: Letter to the Editor

Clopidogrel and acetylsalicylic acid are cornerstones of treatment of the acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI) [1]. The problem of clopidogrel resistance was the object of numerous studies which showed that high platelet reactivity (HPR) in patients treated with this drug is a strong predictor of the risk of ischemic events in patients undergoing PCI [2]; [3]; [4]; [5]; [6]. Matetzky and colleagues showed that 25% of patients undergoing PCI after a previous STEMI were resistant to clopidogrel and therefore at an increased risk of adverse cardiovascular events [7].